1. Home
  2. EQIX vs VRTX Comparison

EQIX vs VRTX Comparison

Compare EQIX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equinix Inc. REIT

EQIX

Equinix Inc. REIT

HOLD

Current Price

$1,079.14

Market Cap

107.0B

Sector

Real Estate

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$453.98

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQIX
VRTX
Founded
1998
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
EDP Services
Sector
Real Estate
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
107.0B
115.7B
IPO Year
2000
2006

Fundamental Metrics

Financial Performance
Metric
EQIX
VRTX
Price
$1,079.14
$453.98
Analyst Decision
Strong Buy
Buy
Analyst Count
24
29
Target Price
$1,076.87
$539.69
AVG Volume (30 Days)
483.2K
999.4K
Earning Date
04-29-2026
05-04-2026
Dividend Yield
1.90%
N/A
EPS Growth
61.88
836.54
EPS
4.20
4.02
Revenue
$5,998,545,000.00
$2,488,652,000.00
Revenue This Year
$12.35
$10.79
Revenue Next Year
$8.88
$10.47
P/E Ratio
$258.06
$111.52
Revenue Growth
7.85
46.20
52 Week Low
$710.52
$362.50
52 Week High
$1,128.68
$509.98

Technical Indicators

Market Signals
Indicator
EQIX
VRTX
Relative Strength Index (RSI) 57.50 61.97
Support Level $1,045.00 $449.40
Resistance Level $1,097.44 $464.15
Average True Range (ATR) 24.54 9.90
MACD -5.65 3.55
Stochastic Oscillator 43.99 99.51

Price Performance

Historical Comparison
EQIX
VRTX

About EQIX Equinix Inc. REIT

Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: